Verrica Completes Enrollment in Pivotal COVE-2 Warts Trial; Topline Data Due Q1 2027
VRCA sits 45% above its 52-week low of $3.28.
Summary
Verrica has completed enrollment in COVE-2, the first of two pivotal Phase 3 trials for YCANTH in common warts. A per-protocol interim analysis found no additional patients are needed, and the second trial, COVE-3, is already over 50% enrolled. Topline data from COVE-2 is expected in Q1 2027, with COVE-3 data by mid-2027. This is a meaningful clinical milestone for a company with a going concern warning and a market cap under $100M. The common warts indication represents a large unmet need with no FDA-approved prescription therapy, and success could significantly expand YCANTH's commercial opportunity. The company's cash runway extends into 2028, but the trial results will be critical for the stock. Insider buying in August suggests management confidence ahead of these data readouts.
At the time of this announcement, VRCA was trading at $4.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.3M. The 52-week trading range was $3.28 to $9.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.